Market Place
Sourcing Support
Pharming Group to participate in Nov investor conference
05 Nov 2024 //
GLOBENEWSWIRE
Pharming Group Q3 2024 Financial Results and Business Update
24 Oct 2024 //
GLOBENEWSWIRE
Pharming Group Announces Starts Ph2 Trial Of Leniolisib For PIDs
10 Oct 2024 //
GLOBENEWSWIRE
Pharming Gets UK Marketing Authorization For Joenja
26 Sep 2024 //
GLOBENEWSWIRE
Pharming Group to participate in September investor conferences
04 Sep 2024 //
GLOBENEWSWIRE
Pharming Reports H1 2024 Results And Business Update
01 Aug 2024 //
GLOBENEWSWIRE
Pharming Group To Report Q2 And H1 2024 Results On August 1
18 Jul 2024 //
GLOBENEWSWIRE
Pharming Group to participate in June investor conferences
03 Jun 2024 //
GLOBENEWSWIRE
Pharming Updates On Leniolisib Review For APDS In Europe
30 May 2024 //
GLOBENEWSWIRE
Pharming Group Reports 2024 Annual Shareholder Meeting Results
21 May 2024 //
GLOBENEWSWIRE
Pharming Group to participate in May investor conference
20 May 2024 //
GLOBENEWSWIRE
Pharming Announces Early Redemption Of Remaining €125M 2025 Convertible Bonds
15 May 2024 //
GLOBENEWSWIRE
Pharming Group Q1 2024 Results, Business Update
08 May 2024 //
GLOBENEWSWIRE
Pharming Honored as NORD Innovator
24 Apr 2024 //
GLOBENEWSWIRE
Pharming Group to report first quarter 2024 financial results on May 8
24 Apr 2024 //
GLOBENEWSWIRE
Pharming Announces Repurchase Of €125M 2025 Convertible Bonds
19 Apr 2024 //
GLOBENEWSWIRE
Pharming Group reports fourth quarter and full year 2023 financial results
14 Mar 2024 //
GLOBENEWSWIRE
Pharming Group to participate in February investor conferences
08 Feb 2024 //
GLOBENEWSWIRE
Pharming announces updated full year 2023 guidance
08 Jan 2024 //
GLOBENEWSWIRE
Pharming Group announces development plans for leniolisib
13 Dec 2023 //
GLOBENEWSWIRE
Pharming announces development plans for leniolisib for additional PIDs
13 Dec 2023 //
GLOBENEWSWIRE
Pharming announces first patient dosed in pediatric trial for leniolisib
21 Nov 2023 //
GLOBENEWSWIRE
Pharming Group provides updates on EMA regulatory review of leniolisib MAA
10 Nov 2023 //
GLOBENEWSWIRE
Pharming announces presentations at Primary Immunodeficiencies Congress
07 Nov 2023 //
GLOBENEWSWIRE
Pharming Group to participate in November investor conferences
01 Nov 2023 //
GLOBENEWSWIRE
Pharming Group reports third quarter 2023 financial results
26 Oct 2023 //
GLOBENEWSWIRE
Pharming Group to report third quarter 2023 financial results on October 26
12 Oct 2023 //
GLOBENEWSWIRE
Pharming Group reports on results of the 2023 Extraordinary General Meeting
25 Sep 2023 //
GLOBENEWSWIRE
Pharming Group to participate in September investor conferences
24 Aug 2023 //
PR NEWSWIRE
Pharming announces first patient enrolled in Phase III trial of leniolisib
09 Aug 2023 //
PR NEWSWIRE
Pharming to nominate industry leader Dr. Richard Peters as Chairman of the Board
17 Jul 2023 //
PR NEWSWIRE
Pharming Group to report Q2 and first half 2023 financial results on August 3
13 Jul 2023 //
PR NEWSWIRE
Novartis buys priority review voucher from Pharming for $21M
01 Jun 2023 //
FIERCE BIOTECH
Pharming announces sale of priority review voucher
01 Jun 2023 //
PR NEWSWIRE
Pharming Group to attend the following Investor Conferences in June
25 May 2023 //
PR NEWSWIRE
Pharming to present at 22nd Annual Needham Virtual Healthcare Conference 2023
13 Apr 2023 //
PR NEWSWIRE
Pharming announces the first commercial shipments of Joenja to patients in U.S.
10 Apr 2023 //
PR NEWSWIRE
Pharming Group announces the filing of its 2022 Annual Report and Form 20-F
05 Apr 2023 //
PR NEWSWIRE
Pharming Gets FDA Nod for Joenja
27 Mar 2023 //
CONTRACT PHARMA
Pharming Stock Reaps Significant Gains After Landmark FDA Approval
25 Mar 2023 //
RTTNEWS
Pharming Group reports financial results for full year 2022
16 Mar 2023 //
PR NEWSWIRE
Pharming announces first patient enrolled in pediatric trial of leniolisib
21 Feb 2023 //
PR NEWSWIRE
Pharming provides update on EMA regulatory review of leniolisib for APDS in EU
16 Feb 2023 //
PR NEWSWIRE
Pharming announces positive data from open-label extension study of leniolisib
15 Dec 2022 //
PRNEWSWIRE
Pharming announces publication of data from Phase 3 Study of leniolisib
06 Dec 2022 //
PRNEWSWIRE
Pharming announces presentation of new leniolisib data at ASH Annual Meeting
23 Nov 2022 //
PRNEWSWIRE
Pharming to attend Credit Suisse 31st Annual Healthcare Conference
07 Nov 2022 //
PRNEWSWIRE
Pharming Announces (EMA) Validates its Marketing Authorisation for leniolisib
28 Oct 2022 //
PRNEWSWIRE
Pharming Announces EMA Validates its MAA under Assessment for leniolisib
27 Oct 2022 //
PRNEWSWIRE
Pharming submits a Marketing Authorisation Application to the EMA for Leniolisib
11 Oct 2022 //
PRNEWSWIRE
Pharming Announces FDA Acceptance for Priority Review of its NDA for Leniolisib
28 Sep 2022 //
TAIWANNEWS
Pharming Group reports financial results for the first half of 2022
04 Aug 2022 //
PRESS RELEASE
Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency
02 Aug 2022 //
PRNEWSWIRE
Pharming Group Receives Accelerated Assessment in Europe for leniolisib
01 Aug 2022 //
PRNEWSWIRE
Pharming Group Notice of H1 2022 Results
25 Jul 2022 //
PHARMING
Pharming receives agreement of Paediatric Plan and Promising Innovative Med
25 Apr 2022 //
PRNEWSWIRE
Pharming shares pivotal data on ex-Novartis rare disease drug
02 Apr 2022 //
FIERCEBIOTECH
Pharming reports positive results from phase II/III study of leniolisib
03 Feb 2022 //
PHARMABIZ
Pharming receives positive EMA decision on PIP for leniolisib in Europe
06 Jan 2022 //
YAHOO
